Literature DB >> 24492294

High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.

Yuqi Liu1, Isabelle Caffry1, Jiemin Wu2, Steven B Geng2, Tushar Jain3, Tingwan Sun1, Felicia Reid1, Yuan Cao1, Patricia Estep1, Yao Yu1, Maximiliano Vásquez3, Peter M Tessier2, Yingda Xu1.   

Abstract

The discovery of monoclonal antibodies (mAbs) that bind to a particular molecular target is now regarded a routine exercise. However, the successful development of mAbs that (1) express well, (2) elicit a desirable biological effect upon binding, and (3) remain soluble and display low viscosity at high concentrations is often far more challenging. Therefore, high throughput screening assays that assess self-association and aggregation early in the selection process are likely to yield mAbs with superior biophysical properties. Here, we report an improved version of affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS) that is capable of screening large panels of antibodies for their propensity to self-associate. AC-SINS is based on concentrating mAbs from dilute solutions around gold nanoparticles pre-coated with polyclonal capture (e.g., anti-Fc) antibodies. Interactions between immobilized mAbs lead to reduced inter-particle distances and increased plasmon wavelengths (wavelengths of maximum absorbance), which can be readily measured by optical means. This method is attractive because it is compatible with dilute and unpurified mAb solutions that are typical during early antibody discovery. In addition, we have improved multiple aspects of this assay for increased throughput and reproducibility. A data set comprising over 400 mAbs suggests that our modified assay yields self-interaction measurements that are well-correlated with other lower throughput assays such as cross-interaction chromatography. We expect that the simplicity and throughput of our improved AC-SINS method will lead to improved selection of mAbs with excellent biophysical properties during early antibody discovery.

Keywords:  aggregation; antibody developability; cross-interaction; high-throughput screening; nanoparticle; self-association; self-interaction

Mesh:

Substances:

Year:  2013        PMID: 24492294      PMCID: PMC3984336          DOI: 10.4161/mabs.27431

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  40 in total

1.  Direct measurement of protein osmotic second virial cross coefficients by cross-interaction chromatography.

Authors:  Peter M Tessier; Stanley I Sandler; Abraham M Lenhoff
Journal:  Protein Sci       Date:  2004-04-09       Impact factor: 6.725

Review 2.  Engineering aggregation-resistant antibodies.

Authors:  Joseph M Perchiacca; Peter M Tessier
Journal:  Annu Rev Chem Biomol Eng       Date:  2012-03-29       Impact factor: 11.059

3.  Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis.

Authors:  Xiaoling Wang; Satish K Singh; Sandeep Kumar
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

4.  Self-interaction nanoparticle spectroscopy: a nanoparticle-based protein interaction assay.

Authors:  Peter M Tessier; Jun Jinkoji; Yu-Chia Cheng; Jessica L Prentice; Abraham M Lenhoff
Journal:  J Am Chem Soc       Date:  2008-02-14       Impact factor: 15.419

5.  Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis.

Authors:  R Blake Pepinsky; Laura Silvian; Steven A Berkowitz; Graham Farrington; Alexey Lugovskoy; Lee Walus; John Eldredge; Allan Capili; Sha Mi; Christilyn Graff; Ellen Garber
Journal:  Protein Sci       Date:  2010-05       Impact factor: 6.725

6.  Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates.

Authors:  Shantanu V Sule; Craig D Dickinson; Jirong Lu; Chi-Kin Chow; Peter M Tessier
Journal:  Mol Pharm       Date:  2013-03-08       Impact factor: 4.939

7.  Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.

Authors:  Joseph M Perchiacca; Ali Reza A Ladiwala; Moumita Bhattacharya; Peter M Tessier
Journal:  Protein Eng Des Sel       Date:  2012-07-27       Impact factor: 1.650

8.  Structure-based engineering of a monoclonal antibody for improved solubility.

Authors:  Sheng-Jiun Wu; Jinquan Luo; Karyn T O'Neil; James Kang; Eilyn R Lacy; Gabriela Canziani; Audrey Baker; Maggie Huang; Qing Mike Tang; T Shantha Raju; Steven A Jacobs; Alexey Teplyakov; Gary L Gilliland; Yiqing Feng
Journal:  Protein Eng Des Sel       Date:  2010-06-11       Impact factor: 1.650

9.  Self-interaction chromatography: a tool for the study of protein-protein interactions in bioprocessing environments.

Authors:  S Y Patro; T M Przybycien
Journal:  Biotechnol Bioeng       Date:  1996-10-20       Impact factor: 4.530

10.  Solubility evaluation of murine hybridoma antibodies.

Authors:  Stacey Spencer; Deidra Bethea; T Shantha Raju; Jill Giles-Komar; Yiqing Feng
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

View more
  42 in total

1.  A novel screening method to assess developability of antibody-like molecules.

Authors:  Neeraj Kohli; Nidhi Jain; Melissa L Geddie; Maja Razlog; Lihui Xu; Alexey A Lugovskoy
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  Process optimization and protein engineering mitigated manufacturing challenges of a monoclonal antibody with liquid-liquid phase separation issue by disrupting inter-molecule electrostatic interactions.

Authors:  Qun Du; Melissa Damschroder; Timothy M Pabst; Alan K Hunter; William K Wang; Haibin Luo
Journal:  MAbs       Date:  2019-04-14       Impact factor: 5.857

Review 3.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

4.  In vitro and in silico assessment of the developability of a designed monoclonal antibody library.

Authors:  Adriana-Michelle Wolf Pérez; Pietro Sormanni; Jonathan Sonne Andersen; Laila Ismail Sakhnini; Ileana Rodriguez-Leon; Jais Rose Bjelke; Annette Juhl Gajhede; Leonardo De Maria; Daniel E Otzen; Michele Vendruscolo; Nikolai Lorenzen
Journal:  MAbs       Date:  2019-01-18       Impact factor: 5.857

5.  Biophysical properties of the clinical-stage antibody landscape.

Authors:  Tushar Jain; Tingwan Sun; Stéphanie Durand; Amy Hall; Nga Rewa Houston; Juergen H Nett; Beth Sharkey; Beata Bobrowicz; Isabelle Caffry; Yao Yu; Yuan Cao; Heather Lynaugh; Michael Brown; Hemanta Baruah; Laura T Gray; Eric M Krauland; Yingda Xu; Maximiliano Vásquez; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

6.  Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering.

Authors:  James C Geoghegan; Ryan Fleming; Melissa Damschroder; Steven M Bishop; Hasige A Sathish; Reza Esfandiary
Journal:  MAbs       Date:  2016-04-06       Impact factor: 5.857

7.  Discovery of high affinity anti-ricin antibodies by B cell receptor sequencing and by yeast display of combinatorial VH:VL libraries from immunized animals.

Authors:  Bo Wang; Chang-Han Lee; Erik L Johnson; Christien A Kluwe; Josephine C Cunningham; Hidetaka Tanno; Richard M Crooks; George Georgiou; Andrew D Ellington
Journal:  MAbs       Date:  2016-05-25       Impact factor: 5.857

8.  Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics.

Authors:  Lindsay B Avery; Jason Wade; Mengmeng Wang; Amy Tam; Amy King; Nicole Piche-Nicholas; Mania S Kavosi; Steve Penn; David Cirelli; Jeffrey C Kurz; Minlei Zhang; Orla Cunningham; Rhys Jones; Brian J Fennell; Barry McDonnell; Paul Sakorafas; James Apgar; William J Finlay; Laura Lin; Laird Bloom; Denise M O'Hara
Journal:  MAbs       Date:  2018-01-29       Impact factor: 5.857

9.  Assessment of Antibody Self-Interaction by Bio-Layer-Interferometry as a Tool for Early Stage Formulation Development.

Authors:  Martin Domnowski; Jan Jaehrling; Wolfgang Frieß
Journal:  Pharm Res       Date:  2020-01-08       Impact factor: 4.200

10.  Target-independent variable region mediated effects on antibody clearance can be FcRn independent.

Authors:  Ryan L Kelly; Yao Yu; Tingwan Sun; Isabelle Caffry; Heather Lynaugh; Michael Brown; Tushar Jain; Yingda Xu; K Dane Wittrup
Journal:  MAbs       Date:  2016-09-09       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.